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Purpose: Cutaneous T-cell lymphoma (CTCL) is known to have an excellent response to
radiotherapy, an important treatment modality for this disease. In patients with extremity
and digit involvement, the irregular surface and depth variations create difficulty in deliv-
ering a homogenous dose using electrons. We sought to evaluate photon irradiation with
rice packing as tissue equivalence and determine clinical tolerance and response.
Materials and methods:Three consecutive CTCL patients with extensive lower extremity
involvement including the digits were treated using external beam photon therapy with
rice packing for tissue compensation. The entire foot was treated to 30–40 Gy in 2–3 Gy
per fraction using 6 MV photons prescribed to the mid-plane of an indexed box filled with
rice in which the foot was placed.Treatment tolerance and response were monitored with
clinical evaluation.
Results: All patients tolerated the treatment without treatment breaks. Toxicities included
grade 3 erythema and desquamation with resolution within 4 weeks. No late toxicities were
observed. All patients had a partial response by 4 weeks after therapy with two patients
achieving a complete response. Patients reported improved functionality after treatment.
No local recurrence has been observed.
Conclusion:Tissue compensation with rice packing offers a convenient, inexpensive, and
reproducible method for the treatment of CTCL with highly irregular surfaces.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCL) are a rare subset of pri-
mary extra-nodal non-Hodgkin’s lymphomas of the skin that
derive from mature T-cells, with peak incidence in the 55–
60 years age range. The most common histological subtypes of
CTCL are mycosis fungoides (MF), Sezary syndrome (SS), and
CD30+ lymphoproliferative disorders, such as anaplastic large
cell lymphoma (ALCL) and lymphomatoid papulosis (LyP). Rare
types include adult T-cell lymphoma (ATL), extra-nodal NK/T-
cell lymphoma (ENKTL), and panniculitis-like T-cell lymphoma
(SPTCL) (1–3). CTCL are generally indolent lymphoid neoplasms
that present with recurring symptomatic skin lesions (plaques,
patches, tumors) for which multiple treatment modalities have
been beneficial. For MF, skin-directed therapies, with or without
the addition of systemic therapy, represent an important compo-
nent of the overall management plan across all stages and histolog-
ical subtypes of CTCL. Superficial skin-directed therapy options
include topical steroids, phototherapy, photodynamic therapy, and
radiotherapy (4–6). Systemic therapy options include biologic
therapies, immuno-modulators, and chemotherapy (5, 7).
Cutaneous T-cell lymphomas are exquisitely sensitive to radio-
therapy. Ionizing radiation induces cell death predominantly
by apoptosis in hematopoietic lineages, and is able to achieve
complete response (CR) at a much lower dose compared to
solid cancers. Radiotherapy is known to palliate symptoms and
improve local disease control in cutaneous lymphomas (8–10).
Previously published studies demonstrate that there is a dose–
response relationship, which include a CR of lesions to doses
over 2000 cGy for fractionated regimens (11) and 700 cGy for
single-fraction regimens (12, 13). Various types of radiother-
apy have been utilized for skin irradiation such as kilo-voltage
photons (superficial/orthovoltage), electrons, and mega-voltage
photons with tissue compensation. Electron beam therapy is
advantageous as it reduces deep tissue radiation penetration
and reduces toxicity to visceral organs. For CTCL, electron
beam therapy is most commonly used in the palliative set-
ting, when one or several isolated cutaneous lesions are treated
for symptom control (14, 15). Less commonly, when there is
extensive skin involvement, total skin electron beam irradiation
is employed (16).
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However, for regions with highly irregular surfaces, such as the
feet with digit involvement, electron field setup can prove chal-
lenging with inadequate tumor coverage and excess dose variance.
Photon irradiation with tissue compensation can be utilized here.
Conventional tissue compensation, such as water baths, increases
the risk of infection with prior skin wounds. Here, we describe
methods and preliminary outcome data of photon irradiation with
rice packing in three patients with CTCL and extensive involve-
ment of the entire foot including digits as an alternative to electron
treatment to achieve improved dose homogeneity.
MATERIALS AND METHODS
Between January 2012 and March 2013, three patients presented
with CTCL involving the lower extremity and the digits. Two
patients had advanced MF while one patient had localized ALCL.
One patient had bilateral extremity involvement and two patients
had single extremity involvement. Patient suffered from extremity
pain, swelling, inability to ambulate, wound infections, and pru-
ritus. Patient data and medical histories are provided in Table 1.
Palliative radiotherapy was recommended for symptom palliation
and local disease control.
All three patients were treated using rice as packing mater-
ial. This reduced the risk of open wound infections, provided
immobilization of extremities, and improved homogeneity in dose
delivery. Though direct comparison was not made with other
materials, the reduced infection risk and ease of use with rice pack-
ing were preferred. Institutional review board (IRB) approval was
obtained before patient treatment and data analysis. The density
of the rice packing was evaluated based on the computer tomog-
raphy scan HU value and was equal to that of water (average
HU= 0 with range of± 100 HU). A plastic tank with dimensions
of 18′′× 8′′× 9′′ was utilized with non-slip base for patient A
(Figure 1). After noting difficulty in measuring lateral quantities
in colored plastic and with the angle of the patient’s leg, a cus-
tom container was created and used for the remainder of patients.
This new container used transparent plastic slabs sealed together
for ease in clinical setup and a slanted posterior edge to allow
the leg to rest easily (Figure 2). The container provided sufficient
Table 1 | Patient data and medical histories.
Patient Age/gender Diagnosis Diagnosis
date
Prior treatments Extremity
involvement
RT dose Concurrent CT
A 70 years old M Advanced stage MF 7/2007 Topical steroids, RT, CT,
phototherapy, biologic
Bilateral 30 Gy in 2 Gy/fx None
B 54 years old M Stage IB MF 5/2004 Biologic, RT, topical steroids, CT Left 30 Gy in 3 Gy/fx Romidepsin
C 74 years old M Stage IE ALCL 2010 Surgical resection, CT Left 40 Gy in 2 Gy/fx MTX
MF, mycosis fungoides; ALCL, anaplastic large cell lymphoma; RT, radiotherapy; CT, chemotherapy; Gy/fx, Gray per fraction; MTX, methotrexate.
FIGURE 1 | Clinical setup for patient A.
FIGURE 2 | Clinical setup for patient B.
Frontiers in Oncology | Radiation Oncology February 2015 | Volume 5 | Article 49 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Majithia et al. Cutaneous lymphoma with irregular surfaces
room for the involved extremity and adequate water-equivalent
buildup. The foot was wrapped in a clear wrap with plantar sur-
face flat against base. After the foot was positioned, the container
was filled with rice to the superior border of the treatment field.
All other patients were setup in a similar fashion.
Treatment plans were manually created to deliver two lateral
radiation fields at 90° and 270° gantry angles. Kilo-voltage sim-
ulation images were taken using the Acuity™(Varian Medical
Systems, Palo Alto, CA, USA) system prior to treatment for the
determination of treatment field size and blocks by the physi-
cian (Figure 3). Isocenter was determined on the Acuity system
and markings were made on the skin of patient, as well as on
the plastic tank. MUs were manually calculated based on the
prescription dose, setup distance, and field size, without consider-
ing heterogeneity correction. As shown in Figure 4, 2 MV portal
images were taken for each patient from the two lateral opposed
fields utilizing 6 MV photon energies. A maximum field size of
40 cm× 40 cm was determined for both gantry angles, with MLCs
to shape the beam. Adequate beam flashing was given circumfer-
entially around the foot, to allow large setup uncertainties and dose
buildup. All patients were positioned supine with the leg flexed.
FIGURE 3 | Acuity simulation films for patient C.
FIGURE 4 | MV portal films of left lateral (left) and right lateral (right)
for patient C.
Special arrangements, including vacuum bags and knee cushions,
were used to keep the other leg out of the treatment field. Dur-
ing the course of treatment, weekly portal films were taken for
treatment verification. As shown in Figure 4, bony anatomy was
verified on the portal films with reference to the reticule. Dose was
prescribed to the mid-plane of the plastic tank. Dose prescrip-
tions were 30–40 Gy in 2–3 Gy fractions. Radiation was delivered
using a Siemens MXE Mevatron linear accelerator. Three optically
stimulated luminescence dosimeters (OSLDs) were placed at the
lateral and dorsal aspects of the foot to measure dose directly
at skin surface of all patients. With adequate water-equivalent
buildup, the only setup uncertainty that was not accounted for
was the lateral positioning (i.e., the foot can be off-centered and
closer to one beam but further away from the other). But with the
two-field arrangement at both lateral gantry angles, dose devia-
tion was considered minimal with the lateral positioning offset.
Based on standard radiation practice, the setup was considered
reproducible daily for consecutive treatments. The National Can-
cer Institute Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0 was used to determine the toxicity scale.
The response to radiotherapy was evaluated clinically with pho-
tographs obtained at each follow-up after 1, 3, 6, and 12 months.
The response to therapy has recently been established in “Clinical
End Points and Response Criteria in MF and Sezary Syndrome”
using data from multiple international lymphoma organizations
(17). Since we are only discussing local therapy in this study, in
addition to the CR, partial response (PR), stable disease (SD),
and progressive disease (PD) described by the consensus guide-
lines, we further define “complete local response” as no clinical
evidence of disease or wound in the treatment field and “partial
local response” as >50% reduction of lesion size in the treatment
field.
RESULTS
Dosimetric parameters were first measured. OSLD measurements
at lateral plantar surface revealed an average dose of 221 cGy, or
110.5% of prescription dose, for patient A, suggesting adequate
dose buildup at the skin. Overall, a variation of the radiation dose
received by the skin did not exceed 2–11% of the prescribed dose
due to the use of rice packing in all patients. The setup was repro-
ducible daily for 10–20 consecutive treatments verified by light
field confirmation daily and by portal films weekly. All patients
noticed resolution of initial symptoms by 1–3 months after ther-
apy. All three patients showed a PR by the end of their treatment,
as seen in Figure 5 for patients A and Figure 6 for patient C.
Two patients had complete local response 4 weeks post-treatment,
and the third patient had partial local response after 12 months.
One patient returned for their 20-month assessment and remained
disease free at bilateral feet.
Treatment toxicities included grade 3 erythema, desquama-
tion, pain, and temporary difficulty with ambulation due to
extremity swelling. Acute symptoms subsided by 4 weeks. The
skin remained smooth and well-vascularized without residual
radiation toxicities at 6–12 months, as shown in Figure 5 for
patient A and Figure 6 for patient C. With a median follow-
up of 14 months (range 9–20 months), there have been no local
recurrences within the boundaries of the radiation field. One
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FIGURE 5 | A series of clinical photographs of patient A before treatment (A), immediately after treatment (B), 2 months after treatment (C), and
12 months after treatment (D).
patient passed away <22 months after treatment completion from
progressive systemic disease. The two other patients remain on
systemic therapy.
DISCUSSION
The role of radiotherapy has been well established in cutaneous
B-cell and T-cell lymphoma for palliative symptom management
and local disease control. The majority of published studies review
the role of electron therapy focusing on adequate dose deposi-
tion at the skin surface and a reduced deep tissue toxicity (4,
18, 19). The dose–response relationship in CTCL has been well
documented. In one retrospective review, PR was observed with
a single dose of 100 cGy, but CRs required dosages greater than
or equal to 700 cGy (4, 12). In several retrospective reviews, a
local control rate of 75% at 5 years post-therapy in stage I MF has
been reported. Authors used conventionally fractionated radio-
therapy with 1.8–2 Gy per fraction to a total dose of 20–40 Gy
(10). The role of hypofractionated therapy has been tested by
Neelis et al. among 49 patients (126 disease sites) with cutaneous
B-cell lymphoma and MF who were treated in two fractions of
2–4 Gy per fractions (20). Seventy percent of patients with MF
failed to respond to 4 Gy delivered in two fractions but only 8%
failed to respond when 8 Gy in two fractions were given, suggesting
that higher dose is needed for this group of patients. In a disease
with systemic involvement, systemic therapies are used with some
success.
Disease site coverage with electron radiotherapy may be diffi-
cult due to the presence of air gaps and tissue interfaces such as
in extremities and digits. Electron radiotherapy may be used, but
dose homogeneity may be achieved easier with photon radiother-
apy using a tissue mimetic. In our study, we have used rice packing
as a tissue equivalent compensator to achieve a homogenous dose
distribution and dose buildup at the skin surface. Dosimetric data
done preliminarily in our clinic has demonstrated the equivalence
of rice packing and water in electron density. Rice packing offers a
reproducible and relatively simple clinical setup for patients with
cutaneous lymphoma involving complex surface areas, such as
extremities. The responses observed in our patients are represen-
tative of previously reported data with 100% PR and 75% CR in
the treatment fields. Toxicities are equivalent to those seen tradi-
tionally with electron therapy, including erythema desquamation,
and pain. No significant late toxicities have been observed with a
maximum 20-month follow-up. Drawbacks of photon irradiation
are that there is no sparing of deep tissues and the extremity skin
surface is treated circumferentially. Therefore, this approach is not
suited for tumors requiring higher doses. However, this treatment
appears to be safe in the dose range for cutaneous lymphoma.
Future directions of research include the evaluation of safety and
activity of this approach in larger patient populations and utility
of radio-sensitizing agents concurrently with photon therapy for
extremity irradiation for cutaneous lymphomas and other disease
sites.
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FIGURE 6 | A series of clinical photographs of patient C before
treatment (A), 2 months after treatment (B), 6 months after treatment
(C), and 12 months after treatment (D).
CONCLUSION
Photon irradiation with tissue compensation with rice packing
offers a novel, inexpensive, and reproducible method for treating
CTCL of the extremities when highly irregular surface is involved.
This is a practical method and the outcomes observed in our
patients have been excellent.
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